Market research
XENE Xenon Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 81.2974
- Dividend yield
- Not available
- Beta
- 0.63
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA98420N1050
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 81.2974
- Dividend yield
- Not available
- Beta
- 0.63
About
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the XENE discussion.
5 years, 4 months ago
Xenon Pharmaceuticals Inc is currently in a long term uptrend where the price is trading 16.6% above its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.3.
Xenon Pharmaceuticals Inc's total revenue rose by 54.7% to $5M since the same quarter in the previous year.
Its net income has dropped by 8.3% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 172.8% to $-14M since the same quarter in the previous year.
Based on the above factors, Xenon Pharmaceuticals Inc gets an overall score of 3/5.